2021 MSK Psychopharmacology in Cancer Care: An Update for Clinicians of All Disciplines

AMA PRA Category 1 : 6.75
Start Date :  Apr 10, 2021End Date :  Apr 10, 2021

Organized by :   Memorial Sloan Kettering Cancer Center (MSKCC)

Specialties :   Behavioral Health, Pulmonary Sciences and Critical Care, Nurse Practitioners, Psychiatry, Psychology, Social Worker Clinical

Fees Fee :   Free

Conference Summary

2021 Psychopharmacology in Cancer Care: An Update for Clinicians of All Disciplines is organized by Memorial Sloan Kettering Cancer Center. This live virtual course will be held fully web-based on April 10, 2021.

AMA Credit Designation Statement:

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum activity of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinicians have numerous tools at their disposal to help adult cancer patients dealing with symptoms of depression, anxiety, and other cancer sequelae. Psychiatric medications are most frequently prescribed to cancer patients by oncologists and general practitioners, however psychiatric syndromes are often underdiagnosed and undertreated. Few oncology practices have dedicated psychiatric consultants familiar with the nuances of Psycho-Oncology. Even when patients receive psychotropic medications appropriately, they may have problems that arise before their next oncology visit or before they see the person who prescribed their psychiatric medications. Psychologists, nurses and social workers play an essential role in identifying psychological and physical symptoms as well as both beneficial and problematic medication effects as they provide frontline psychosocial interventions and support for cancer patients.

This course is designed for the non-prescribing psycho-oncology clinician as well as the psychiatrist who is new to the world of Psycho-pharmaco-oncology. Oncologists, palliative care clinicians, advanced practice nurses and oncology nurses will find this course useful as well. The course will focus on key target disorders and symptoms amenable to psychopharmacological intervention, including anxiety, depression, delirium, sleep disturbance, pain, fatigue, and weight and appetite loss. This year, the course will also include updates on COVID-19 related delirium and the use of novel interventions including ketamine, medical marijuana and psilocybin for depression, anxiety and pain. Participants will learn to identify psychological reactions to medical conditions or treatments; psychiatric presentations of medical conditions or treatments; medical presentations of psychiatric conditions and common medical complications of psychiatric conditions or treatments.

Basic information will be presented about medications used to alleviate Quality of Life symptoms that arise in the cancer setting from diagnosis to survivorship or end of life care, and the interface of psychotherapy and medication management. We will review why certain medications are used and why some are avoided, looking at potential benefits, unwanted side effects, and drug-drug interactions, since you may be the first person to identify a serious adverse event. The course will also enhance your ability to provide psychoeducation to patients regarding psychiatric medications.This course is co-sponsored by the MSK Psycho-Oncology Education & Training Institute (POETI).

Participants will learn basic psycho-pharmaco-oncology and how to hone essential clinical and observation skills to improve the quality of life, mental health and safety of their patients by understanding the basics of the psychophysiology of cancer.

Credit Info

  • AMA PRA Category 1 : 6.75
Additional Info

Social Media Info :

Speaker (s)
5 Speaker(s)
Contact Us

Toll free Number

1(800) 826-2059



Chat Assistant

Live Chat